Aktis Oncology, Inc.
AKTS
$18.75
$0.030.16%
NASDAQ
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | -23.68% | ||||
| Total Receivables | 0.00% | ||||
| Inventory | -- | ||||
| Prepaid Expenses | -6.27% | ||||
| Finance Division Loans and Leases Current | -- | ||||
| Total Finance Division Other Current Assets | -- | ||||
| Other Current Assets | -- | ||||
| Total Current Assets | -23.45% | ||||
|
|
|||||
| Total Current Assets | -23.45% | ||||
| Net Property, Plant & Equipment | 30.54% | ||||
| Long-term Investments | -- | ||||
| Goodwill | -- | ||||
| Total Other Intangibles | -- | ||||
| Finance Div Loans & Leases LT | -- | ||||
| Total Finance Div Other LT Assets | -- | ||||
| Total Other Assets | 64.44% | ||||
| Total Assets | -18.79% | ||||
|
|
|||||
| Total Accounts Payable | -9.44% | ||||
| Total Accrued Expenses | 50.40% | ||||
| Short-term Debt | -- | ||||
| Current Portion of Long-Term Debt/Capital Leases | -- | ||||
| Finance Division Debt Current | 1.47% | ||||
| Total Finance Division Other Current Liabilities | 101.16% | ||||
| Total Other Current Liabilities | 101.16% | ||||
| Total Current Liabilities | 65.95% | ||||
|
|
|||||
| Total Current Liabilities | 65.95% | ||||
| Long-Term Debt | -- | ||||
| Short-term Debt | -- | ||||
| Capital Leases | -4.49% | ||||
| Finance Division Debt Non Current | -- | ||||
| Total Finance Division Other Non Current Liabilities | -- | ||||
| Total Other Liabilities | -29.16% | ||||
| Total Liabilities | -3.66% | ||||
|
|
|||||
| Common Stock & APIC | 111.43% | ||||
| Retained Earnings | -68.65% | ||||
| Treasury Stock & Other | -66.13% | ||||
| Total Common Equity | -66.45% | ||||
|
|
|||||
| Preferred Stock Redeemable | -- | ||||
| Preferred Stock Non Redeemable | -- | ||||
| Preferred Stock Convertible | 0.00% | ||||
| Preferred Stock, Others | -- | ||||
| Total Preferred Equity | 0.00% | ||||
|
|
|||||
| Total Common Equity | -66.45% | ||||
| Total Preferred Equity | 0.00% | ||||
| Total Minority Interest | -- | ||||
| Total Equity | -23.76% | ||||
|
|
|||||